Nyt fra tidsskrifterne
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Ingen søgeord valgt.
28 emner vises.
American Journal of Tropical Medicine and Hygiene, 15.09.2021
Tilføjet 15.09.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 105Issue: 3Pages: 545-546
Læs mere Tjek på PubMedAmerican Journal of Tropical Medicine and Hygiene, 15.09.2021
Tilføjet 15.09.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 105Issue: 3Pages: 547-548
Læs mere Tjek på PubMedAmerican Journal of Tropical Medicine and Hygiene, 15.09.2021
Tilføjet 15.09.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 105Issue: 3Pages: 549-550
Læs mere Tjek på PubMedAmerican Journal of Tropical Medicine and Hygiene, 15.09.2021
Tilføjet 15.09.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 105Issue: 3Pages: 551-552
Læs mere Tjek på PubMedAmerican Journal of Tropical Medicine and Hygiene, 15.09.2021
Tilføjet 15.09.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 105Issue: 3Pages: 553-554
Læs mere Tjek på PubMedAmerican Journal of Tropical Medicine and Hygiene, 15.09.2021
Tilføjet 15.09.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 105Issue: 3Pages: 555-556
Læs mere Tjek på PubMedAmerican Journal of Tropical Medicine and Hygiene, 15.09.2021
Tilføjet 15.09.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 105Issue: 3Pages: 557-560
Læs mere Tjek på PubMedAmerican Journal of Tropical Medicine and Hygiene, 15.09.2021
Tilføjet 15.09.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 105Issue: 3Pages: 561-563
Læs mere Tjek på PubMedAmerican Journal of Tropical Medicine and Hygiene, 15.09.2021
Tilføjet 15.09.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 105Issue: 3Pages: 564-572
Læs mere Tjek på PubMedAmerican Journal of Tropical Medicine and Hygiene, 15.09.2021
Tilføjet 15.09.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 105Issue: 3Pages: 573-583
Læs mere Tjek på PubMedAmerican Journal of Tropical Medicine and Hygiene, 15.09.2021
Tilføjet 15.09.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 105Issue: 3Pages: 584-595
Læs mere Tjek på PubMedAmerican Journal of Tropical Medicine and Hygiene, 15.09.2021
Tilføjet 15.09.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 105Issue: 3Pages: 596-599
Læs mere Tjek på PubMedAmerican Journal of Tropical Medicine and Hygiene, 15.09.2021
Tilføjet 15.09.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 105Issue: 3Pages: 600-610
Læs mere Tjek på PubMedAmerican Journal of Tropical Medicine and Hygiene, 15.09.2021
Tilføjet 15.09.2021
Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 105Issue: 3Pages: 611-621
Læs mere Tjek på PubMedDreher, A., Pietrowsky, R., Loerbroks, A.
BMJ Open, 15.09.2021
Tilføjet 15.09.2021
Objectives
The COVID-19 pandemic has posed great challenges to medical professionals worldwide. Dental assistants (DAs) are at exceptionally high risk of infection with SARS-CoV-2 due to frequent and close patient contact and involvement in various high-risk dental procedures. This study aimed to investigate attitudes, stressors and work outcomes among DAs from all over Germany at the peak of cases in spring 2020.
Design
Cross-sectional study. Descriptive analysis and logistic regression.
Setting
Dental, maxillofacial surgery and orthodontic practices across Germany, April 2020.
Participants
Participants aged 18 years and above and currently working as DAs in Germany.
Primary and secondary outcome measures
A self-devised online questionnaire was employed comprising questions on SARS-CoV-2-related attitudes, stressors and work outcomes. Validated scales assessed symptoms of depression and anxiety.
Results
Among 1481 participating DAs (median age 35 years, 98.4% female, 91.8% working in dental practices), major stressors were uncertainty about the pandemic’s temporal scope (97.9% agreement, n=1450), uncertainty about one’s financial situation (87.8%, n=1301), uncertainty about how to act correctly (87.6%, n=1298) and thoughts about a possible infection during work (83.8%, n=1241). Forty-two per cent of DAs (n=622) felt sufficiently prepared for dealing with patients with SARS-CoV-2. Only 17.5% (n=259) agreed that material for personal protection was sufficiently available. Multivariable logistic regression analyses suggested that working in a dental practice, compared with orthodontic and maxillofacial surgery practices, was significantly associated with uncertainty about one’s financial situation (OR 2.13 (95% CI 1.33 to 3.44)) and with the reported availability of personal protective equipment (PPE) (0.55 (0.36 to 0.84)).
Conclusions
Training about correct behaviour of DAs during future infectious disease outbreaks is needed, especially for DAs working in dental practices. In the future, it will also be necessary to strengthen supply chains to ensure that PPE is sufficiently available in a timely manner.
Læs mere Tjek på PubMedHirner, S., Pigoga, J. L., Naidoo, A. V., Calvello Hynes, E. J., Omer, Y. O., Wallis, L. A., Bills, C. B.
BMJ Open, 15.09.2021
Tilføjet 15.09.2021
Objectives
Purposefully designed and validated screening, triage, and severity scoring tools are needed to reduce mortality of COVID-19 in low-resource settings (LRS). This review aimed to identify currently proposed and/or implemented methods of screening, triaging, and severity scoring of patients with suspected COVID-19 on initial presentation to the healthcare system and to evaluate the utility of these tools in LRS.
Design
A scoping review was conducted to identify studies describing acute screening, triage, and severity scoring of patients with suspected COVID-19 published between 12 December 2019 and 1 April 2021. Extracted information included clinical features, use of laboratory and imaging studies, and relevant tool validation data.
Participant
The initial search strategy yielded 15 232 articles; 124 met inclusion criteria.
Results
Most studies were from China (n=41, 33.1%) or the United States (n=23, 18.5%). In total, 57 screening, 23 triage, and 54 severity scoring tools were described. A total of 51 tools–31 screening, 5 triage, and 15 severity scoring—were identified as feasible for use in LRS. A total of 37 studies provided validation data: 4 prospective and 33 retrospective, with none from low-income and lower middle-income countries.
Conclusions
This study identified a number of screening, triage, and severity scoring tools implemented and proposed for patients with suspected COVID-19. No tools were specifically designed and validated in LRS. Tools specific to resource limited contexts is crucial to reducing mortality in the current pandemic.
Læs mere Tjek på PubMedZhang, M., Li, Y., Fan, Z., Shen, D., Huang, X., Yu, Q., Liu, M., Ren, F., Wang, X., Dai, L., Wang, P., Ye, H., Shi, J., Yang, X., Zhang, S., Zhang, J.
BMJ Open, 15.09.2021
Tilføjet 15.09.2021
Objectives
The health-related quality of life (HRQoL) and utilities of patients with chronic hepatitis B (CHB) virus infection, including compensated cirrhosis (CC), decompensated cirrhosis (DC) and different stages of hepatocellular carcinoma (HCC), have not been well described in China. This study aimed to evaluate HRQoL and utilities and provide parameters for the economic evaluation of CHB-related diseases.
Methods
We conducted a multicentre cross-sectional and study to measure the HRQoL of patients with CHB, CC, DC and HCC using the Chinese short form (SF) 36 health survey V.2. The utilities were extracted based on the SF-six dimension scoring model. Multivariable regression analyses identified the effects on HRQoL.
Results
A total of 1071 patients (639 with CHB, 125 with CC, 85 with DC and 222 with HCC) were invited to complete the questionnaire. Physical HRQoL was not impaired in the CHB stage, while mental HRQoL was significantly impaired. Physical composite summary scores have a more significant decrease than mental composite summary scores at the advanced stages (CC, DC and HCC). The utility scores of CHB only, CC, DC and HCC were 0.773, 0.750, 0.683 and 0.640, respectively. The utility scores in the early, middle and terminal stages of HCC were 0.656, 0.635 and 0.615, respectively.
Conclusion
Slowing the progress of CHB-related diseases and providing psychological support early are the key points to improving the quality of life with the diseases. The utility values estimated in this study can provide a vital instrument for cost-effectiveness studies on CHB-related diseases.
Læs mere Tjek på PubMedWade, A. N., Payne, C. F., Berkman, L., Chang, A., Gomez-Olive, F. X., Kabudula, C., Kahn, K., Salomon, J. A., Tollman, S., Witham, M., Davies, J.
BMJ Open, 15.09.2021
Tilføjet 15.09.2021
Objectives
Multimorbidity is associated with mortality in high-income countries. Our objective was to investigate the relationship between multimorbidity (≥2 of the following chronic medical conditions: hypertension, diabetes, dyslipidaemia, anaemia, HIV, angina, depression, post-traumatic stress disorder, alcohol dependence) and all-cause mortality in an older, rural black South African population. We further investigated the relationship between HIV multimorbidity (HIV as part of the multimorbidity cluster) and mortality, while testing for the effect of frailty in all models.
Design
Population cohort study.
Setting
Agincourt subdistrict of Mpumalanga province, South Africa.
Participants
4455 individuals (54.7% female), aged ≥40 years (median age 61 years, IQR 52–71) and resident in the study area.
Primary and secondary outcome measures
The primary outcome measure was time to death and the secondary outcome measure was likelihood of death within 2 years of the initial study visit. Mortality was determined during annual population surveillance updates.
Results
3157 individuals (70.9%) had multimorbidity; 29% of these had HIV. In models adjusted for age and sociodemographic factors, multimorbidity was associated with greater risk of death (women: HR 1.72; 95% CI: 1.18 to 2.50; men: HR 1.46; 95% CI: 1.09 to 1.95) and greater odds of dying within 2 years (women: OR 2.34; 95% CI: 1.32 to 4.16; men: OR 1.51; 95% CI: 1.02 to 2.24). HIV multimorbidity was associated with increased risk of death compared with non-HIV multimorbidity in men (HR 1.93; 95% CI: 1.05 to 3.54), but was not statistically significant in women (HR 1.85; 95% CI: 0.85 to 4.04); when detectable, HIV viral loads were higher in men (p=0.021). Further adjustment for frailty slightly attenuated the associations between multimorbidity and mortality risk (women: HR 1.55; 95% CI: 1.06 to 2.26; men: HR 1.36; 95% CI: 1.01 to 1.82), but slightly increased associations between HIV multimorbidity and mortality risk.
Conclusions
Multimorbidity is associated with mortality in this older black South African population. Health systems which currently focus on HIV should be reorganised to optimise identification and management of other prevalent chronic diseases.
Læs mere Tjek på PubMedChan-Cuzydlo, A., Harrison, D. J., Pike, B. L., Currie, B. J., Mayo, M., Salvador, M. G., Hulsey, W. R., Azzarello, J., Ellis, J., Kim, D., King-Lewis, W., Smith, J. N., Rodriguez, B., Maves, R. C., Lawler, J. V., Schully, K. L.
BMJ Open, 15.09.2021
Tilføjet 15.09.2021
Purpose
In 2012, US Marines and Sailors began annual deployments to Australia to participate in joint training exercises with the Australian Defence Force and other partners in the region. During their training, US service members are exposed to a variety of infectious disease threats not normally encountered by American citizens. This paper describes a cohort of US Marines and Sailors enrolled during five rotations to Australia between 2016 and 2020.
Participants
Study participation is strictly voluntary. Group informational sessions are held prior to deployment to describe the study structure and goals, as well as the infectious disease threats that participants may encounter while in Australia. All participants provided written informed consent. Consented participants complete a pre-deployment questionnaire to collect data including basic demographic information, military occupational specialty, travel history, family history, basic health status and personal habits such as alcohol consumption. Blood is collected for serum, plasma and peripheral blood mononuclear cells (PBMC) processing. Data and specimen collection is repeated up to three times: before, during and after deployment.
Findings to date
From the five rotations that comprised the 2016–2020 Marine Rotational Force-Darwin, we enrolled 1289 volunteers. Enrolments during this period were overwhelmingly white male under the age of 24 years. Most of the enrollees were junior enlisted and non-commissioned officers, with a smaller number of staff non-commissioned officers and commissioned officers, and minimal warrant officers. Over half of the enrollees had occupational specialty designations for infantry.
Future plans
In the future, we will screen samples for serological evidence of infection with Burkholderia pseudomallei, Coxiella burnetii, Ross River virus, SARS-CoV-2 and other operationally relevant pathogens endemic in Australia. Antigenic stimulation assays will be performed on PBMCs collected from seropositive individuals to characterise the immune response to these infections in this healthy American population.
Læs mere Tjek på PubMedRalph, A. P., Webb, R., Moreland, N. J., McGregor, R., Bosco, A., Broadhurst, D., Lassmann, T., Barnett, T. C., Benothman, R., Yan, J., Remenyi, B., Bennett, J., Wilson, N., Mayo, M., Pearson, G., Kollmann, T., Carapetis, J. R.
BMJ Open, 15.09.2021
Tilføjet 15.09.2021
Introduction
The absence of a diagnostic test for acute rheumatic fever (ARF) is a major impediment in managing this serious childhood condition. ARF is an autoimmune condition triggered by infection with group A Streptococcus. It is the precursor to rheumatic heart disease (RHD), a leading cause of health inequity and premature mortality for Indigenous peoples of Australia, New Zealand and internationally.
Methods and analysis
‘Searching for a Technology-Driven Acute Rheumatic Fever Test’ (START) is a biomarker discovery study that aims to detect and test a biomarker signature that distinguishes ARF cases from non-ARF, and use systems biology and serology to better understand ARF pathogenesis. Eligible participants with ARF diagnosed by an expert clinical panel according to the 2015 Revised Jones Criteria, aged 5–30 years, will be recruited from three hospitals in Australia and New Zealand. Age, sex and ethnicity-matched individuals who are healthy or have non-ARF acute diagnoses or RHD, will be recruited as controls. In the discovery cohort, blood samples collected at baseline, and during convalescence in a subset, will be interrogated by comprehensive profiling to generate possible diagnostic biomarker signatures. A biomarker validation cohort will subsequently be used to test promising combinations of biomarkers. By defining the first biomarker signatures able to discriminate between ARF and other clinical conditions, the START study has the potential to transform the approach to ARF diagnosis and RHD prevention.
Ethics and dissemination
The study has approval from the Northern Territory Department of Health and Menzies School of Health Research ethics committee and the New Zealand Health and Disability Ethics Committee. It will be conducted according to ethical standards for research involving Indigenous Australians and New Zealand Māori and Pacific Peoples. Indigenous investigators and governance groups will provide oversight of study processes and advise on cultural matters.
Læs mere Tjek på PubMedInfection, 15.09.2021
Tilføjet 15.09.2021
Abstract
Purpose
Blood culture contamination is still a frequently observed event and may lead to unnecessary antibiotic prescriptions and additional hazards and costs. However, in patients hospitalized in tertiary care, true bacteremias for pathogens that are classically considered as contaminants can be observed. We assessed the diagnostic accuracy of procalcitonin for differentiating blood culture contamination from bacteremia in patients with positive blood cultures for potential contaminants.
Methods
We carried out a retrospective, cross-sectional, observational study on consecutive patients hospitalized between January 2016 and May 2019 at the University Hospital of Nancy and who had a positive peripheral blood culture for a pathogen classically considered as a potential contaminant.
Results
During the study period, 156 patients were screened, and 154 were retained in the analysis. Among the variables that were significantly associated with a diagnosis of blood culture contamination in univariate analyses, four were maintained in multivariate logistic regression analysis: a number of positive blood culture bottles ≤ 2 (OR 23.76; 95% CI 1.94–291.12; P = 0.01), procalcitonin < 0.1 ng/mL (OR 14.88; 95% CI 1.62–136.47; P = 0.02), non-infection-related admission (OR 13.00; 95% CI 2.17–77.73; P = 0.005), and a percentage of positive blood culture bottles ≤ 25% (OR 12.15; 95% CI 2.02–73.15; P = 0.006).
Conclusions
These data provide new evidence on the usefulness of plasma procalcitonin as a reliable diagnostic biomarker in the diagnostic algorithm of peripheral blood culture contamination among patients hospitalized in tertiary care.
Clinical trial
ClinicalTrials.gov #NCT04573894.
Læs mere Tjek på PubMedInfection, 15.09.2021
Tilføjet 15.09.2021
Abstract
Purpose
Since the first Italian case of SARS-CoV-2 was detected in Lombardy (Northern Italy) Italy quickly became one of the worst-affected European countries, with a severe impact on health-care workers (HCWs). In the first epidemic, HCWs accounted for 12% of all national COVID-19 cases. We evaluated the burden of COVID-19 among HCWs and other non-health-care workers (nHCWs) in a large Italian hospital.
Methods
From March 1st to May 31st 2020, we performed a retrospective study at ASST Civil Hospital, in the Province of Brescia, Lombardy. The study population included all hospital personnel (n = 9265), categorized by professional status.
Results
A SARS-CoV-2 test was performed in 3572 workers (38.5%), with a positive result in 552 (5.9% of all hospital personnel). The temporal trend of SARS-CoV-2 cases in hospital staff broadly reflected that in the community, with a great majority of infections occurred during March 2020 (87.7%). From April onward, a steep decrease of positive cases was observed among hospital personnel, while in the community the decrease was much slower. Medical doctors (8.9%) and nurses (8.5%) were the most affected professional categories with a significantly higher risk of SARS-CoV-2 infection (OR 1.436 and OR 1.410, respectively p < 0.0001). HCWs in COVID-19 units presented a significantly higher risk of infection compared to HCWs in non-COVID units (p < 0.001).
Conclusion
HCWs were severely affected by the COVID-19 epidemic, probably associated with an overwhelming burden of work and lack of preparedness in prevention of nosocomial transmission of the infection. The rapid decrease of COVID-19 spread in the hospital, registered before the one in the community, suggests that the adopted preventive measures were effective.
Læs mere Tjek på PubMedInfection, 14.09.2021
Tilføjet 15.09.2021
Ignacio Barandalla, Carmen Alvarez, Pablo Barreiro, Carmen de Mendoza, Rubén González-Crespo, Vicente Soriano
International Journal of Infectious Diseases, 15.09.2021
Tilføjet 15.09.2021
The recent global spreading of SARS-CoV-2 infection in humans is unprecedented in medicine (Morens et al., 2020). At the end of June 2021, over 180 million cases had been reported worldwide with nearly 4 million deaths. In Spain, these figures were of nearly 4 million confirmed cases and over 80,000 deaths. In the absence of effective antiviral agents against SARS-CoV-2, the advent of vaccines has been eagerly awaited. The first vaccines achieved emergency approval in December 2020 after proving significant protection for development of severe COVID-19 in clinical trials [Polack et al.
Læs mere Tjek på PubMedVimvara Vacharathit, Sirawat Srichatrapimuk, Suwimon Manopwisedjaroen, Suppachok Kirdlarp, Chanya Srisaowakarn, Chavachol Setthaudom, Nanthicha Inrueangsri, Prapaporn Pisitkun, Mongkol Kunakorn, Suradej Hongeng, Somnuek Sungkanuparph, Arunee Thitithanyanont
International Journal of Infectious Diseases, 15.09.2021
Tilføjet 15.09.2021
‘Coronavirus Disease 2019’ (COVID-19), caused by the highly transmissible and pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has so far infected about 220 million people worldwide, leading to more than 4.6 million deaths within a period of 21 months. In Thailand, approximately 1.3 million cases and over 13,000 deaths have been confirmed at the time of writing (2021). The ongoing COVID-19 pandemic has taken a significant toll on global public health and economy, calling for a deeper understanding of immune correlates of protection against SARS-CoV-2 that may be vital for implementation of mitigation strategies and development of treatments and vaccines.
Læs mere Tjek på PubMedTom Lutalo, Aminah Nalumansi, Denis Olara, John Kayiwa, Bernard Ogwang, Emmanuel Odwilo, Christine Watera, Stephen Balinandi, Jocelyn Kiconco, Joweria Nakaseegu, Jennifer Serwanga, Bernard Kikaire, Deogratius Ssemwanga, Brendah Abiko, Christopher Nsereko, Matthew Cotten, Joshua Buule, Julius Lutwama, Robert Downing, Pontiano Kaleebu
International Journal of Infectious Diseases, 15.09.2021
Tilføjet 15.09.2021
Coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization (WHO) on March 11, 2020. Globally as of September 1st, 2021, there have been nearly 218 million cases reported to WHO with over 4.5 million deaths while in Uganda 99,408 cases with over 3000 deaths have been recorded (WHO 2021). Since this evaluation, the number of new cases and deaths continued to rise.
Læs mere Tjek på PubMedAngela Choi, Matthew Koch, Kai Wu, Laurence Chu, LingZhi Ma, Anna Hill, Naveen Nunna, Wenmei Huang, Judy Oestreicher, Tonya Colpitts, Hamilton Bennett, Holly Legault, Yamuna Paila, Biliana Nestorova, Baoyu Ding, David Montefiori, Rolando Pajon, Jacqueline M. Miller, Brett Leav, Andrea Carfi, Roderick McPhee, Darin K. Edwards
Nature, 15.09.2021
Tilføjet 15.09.2021
Nature Medicine, Published online: 15 September 2021; doi:10.1038/s41591-021-01527-y
Preliminary and exploratory analyses show that a third dose of the COVID-19 vaccine mRNA-1273 or variant-modified boosters can boost levels of neutralizing antibodies against SARS-CoV-2 variants.
Læs mere Tjek på PubMedIttai Dayan, Holger R. Roth, Aoxiao Zhong, Ahmed Harouni, Amilcare Gentili, Anas Z. Abidin, Andrew Liu, Anthony Beardsworth Costa, Bradford J. Wood, Chien-Sung Tsai, Chih-Hung Wang, Chun-Nan Hsu, C. K. Lee, Peiying Ruan, Daguang Xu, Dufan Wu, Eddie Huang, Felipe Campos Kitamura, Griffin Lacey, Gustavo César de Antônio Corradi, Gustavo Nino, Hao-Hsin Shin, Hirofumi Obinata, Hui Ren, Jason C. Crane, Jesse Tetreault, Jiahui Guan, John W. Garrett, Joshua D. Kaggie, Jung Gil Park, Keith Dreyer, Krishna Juluru, Kristopher Kersten, Marcio Aloisio Bezerra Cavalcanti Rockenbach, Marius George Linguraru, Masoom A. Haider, Meena AbdelMaseeh, Nicola Rieke, Pablo F. Damasceno, Pedro Mario Cruz e Silva, Pochuan Wang, Sheng Xu, Shuichi Kawano, Sira Sriswasdi, Soo Young Park, Thomas M. Grist, Varun Buch, Watsamon Jantarabenjakul, Weichung Wang, Won Young Tak, Xiang Li, Xihong Lin, Young Joon Kwon, Abood Quraini, Andrew Feng, Andrew N. Priest, Baris Turkbey, Benjamin Glicksberg, Bernardo Bizzo, Byung Seok Kim, Carlos Tor-Díez, Chia-Cheng Lee, Chia-Jung Hsu, Chin Lin, Chiu-Ling Lai, Christopher P. Hess, Colin Compas, Deepeksha Bhatia, Eric K. Oermann, Evan Leibovitz, Hisashi Sasaki, Hitoshi Mori, Isaac Yang, Jae Ho Sohn, Krishna Nand Keshava Murthy, Li-Chen Fu, Matheus Ribeiro Furtado de Mendonça, Mike Fralick, Min Kyu Kang, Mohammad Adil, Natalie Gangai, Peerapon Vateekul, Pierre Elnajjar, Sarah Hickman, Sharmila Majumdar, Shelley L. McLeod, Sheridan Reed, Stefan Gräf, Stephanie Harmon, Tatsuya Kodama, Thanyawee Puthanakit, Tony Mazzulli, Vitor Lima de Lavor, Yothin Rakvongthai, Yu Rim Lee, Yuhong Wen, Fiona J. Gilbert, Mona G. Flores, Quanzheng Li
Nature, 15.09.2021
Tilføjet 15.09.2021
Nature Medicine, Published online: 15 September 2021; doi:10.1038/s41591-021-01506-3
Federated learning, a method for training artificial intelligence algorithms that protects data privacy, was used to predict future oxygen requirements of symptomatic patients with COVID-19 using data from 20 different institutes across the globe.
Læs mere Tjek på PubMed